Incyte Q3 adjusted loss per share beats estimates
Overview
U.S. biopharmaceutical firm's Q3 revenue rose 14% yr/yr, driven by growth in core products
Q3 adjusted loss per share beat analyst expectations
Company raised full-year 2026 net sales guidance for Opzelura, Hematology and Oncology, and total net sales
Outlook
Incyte raises 2026 total net sales guidance to $5.21-$5.3 bln from $5.13-$5.26 bln
Company lifts 2026 Opzelura net sales forecast to $1.1-$1.12 bln from $1.05-$1.1 bln
2026 Hematology and Oncology net sales outlook increased to $890-$910 mln from $860-$890 mln
Result Drivers
OPZELURA DEMAND AND PRICING - Co said Q3 Opzelura sales rose due to higher patient demand in atopic dermatitis and vitiligo and improved net pricing
HEMATOLOGY AND ONCOLOGY DEMAND - Co said Q3 Hematology and Oncology sales grew on higher demand for Niktimvo, Zynyz and Monjuvi/Minjuvi
JAKAFI DEMAND - Co said Q3 Jakafi sales rose due to higher paid demand and growth across all indications
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Adjusted Loss Per Share | Beat | $3.60 | $3.85 (17 Analysts) |
Q3 Loss Per Share | $3.86 | ||
Q3 Adjusted Operating Income | Beat | -$629.72 mln | -$786.67 mln (13 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 16 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Incyte Corp is $130.00, about 11.2% above its October 28 closing price of $116.87
The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 14 three months ago
Reuters Recommended Reads
Oct 28 - Biogen tops quarterly estimates on rare-disease drug strength
Oct 29 - Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges
Oct 28 - GSK tops third-quarter estimates as new medicines drive growth, keeps outlook
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)